Literature DB >> 22398293

The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry.

Chwan Hong Foo1, J Charles Whitbeck, Manuel Ponce-de-León, Wan Ting Saw, Gary H Cohen, Roselyn J Eisenberg.   

Abstract

Vaccinia virus (VACV) L1 is a myristoylated envelope protein which is required for cell entry and the fusion of infected cells. L1 associates with members of the entry-fusion complex (EFC), but its specific role in entry has not been delineated. We recently demonstrated (Foo CH, et al., Virology 385:368-382, 2009) that soluble L1 binds to cells and blocks entry, suggesting that L1 serves as the receptor-binding protein for entry. Our goal is to identify the structural domains of L1 which are essential for its functions in VACV entry. We hypothesized that the myristate and the conserved residues at the N terminus of L1 are critical for entry. To test our hypothesis, we generated mutants in the N terminus of L1 and used a complementation assay to evaluate their ability to rescue infectivity. We also assessed the myristoylation efficiency of the mutants and their ability to interact with the EFC. We found that the N terminus of L1 constitutes a region that is critical for the infectivity of VACV and for myristoylation. At the same time, the nonmyristoylated mutants were incorporated into mature virions, suggesting that the myristate is not required for the association of L1 with the viral membrane. Although some of the mutants exhibited altered structural conformations, two mutants with impaired infectivity were similar in conformation to wild-type L1. Importantly, these two mutants, with changes at A4 and A5, undergo myristoylation. Overall, our results imply dual differential roles for myristate and the amino acids at the N terminus of L1. We propose a myristoyl switch model to describe how L1 functions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398293      PMCID: PMC3347306          DOI: 10.1128/JVI.06703-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

1.  Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.

Authors:  Hua-Poo Su; Joseph W Golden; Apostolos G Gittis; Jay W Hooper; David N Garboczi
Journal:  Virology       Date:  2007-08-03       Impact factor: 3.616

2.  The vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry.

Authors:  R Jeremy Nichols; Eleni Stanitsa; Bethany Unger; Paula Traktman
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

3.  A conserved sequence within the H2 subunit of the vaccinia virus entry/fusion complex is important for interaction with the A28 subunit and infectivity.

Authors:  Gretchen E Nelson; Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

4.  Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies.

Authors:  Gretchen E Nelson; Jerry R Sisler; Dev Chandran; Bernard Moss
Journal:  Virology       Date:  2008-09-11       Impact factor: 3.616

5.  Signal peptide requirements for lymphocytic choriomeningitis virus glycoprotein C maturation and virus infectivity.

Authors:  Sabrina Schrempf; Marc Froeschke; Tsanan Giroglou; Dorothee von Laer; Bernhard Dobberstein
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

6.  Vaccinia virus l1 protein is required for cell entry and membrane fusion.

Authors:  Himani Bisht; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

7.  Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex.

Authors:  Grazyna Kochan; David Escors; José Manuel González; Jose Maria Casasnovas; Mariano Esteban
Journal:  Cell Microbiol       Date:  2007-08-15       Impact factor: 3.715

8.  Vaccinia virus exhibits cell-type-dependent entry characteristics.

Authors:  J Charles Whitbeck; Chwan-Hong Foo; Manuel Ponce de Leon; Roselyn J Eisenberg; Gary H Cohen
Journal:  Virology       Date:  2009-01-21       Impact factor: 3.616

9.  Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans.

Authors:  Chwan Hong Foo; Huan Lou; J Charles Whitbeck; Manuel Ponce-de-León; Doina Atanasiu; Roselyn J Eisenberg; Gary H Cohen
Journal:  Virology       Date:  2009-01-21       Impact factor: 3.616

10.  The Jpred 3 secondary structure prediction server.

Authors:  Christian Cole; Jonathan D Barber; Geoffrey J Barton
Journal:  Nucleic Acids Res       Date:  2008-05-07       Impact factor: 16.971

View more
  7 in total

1.  Protein Primary Structure of the Vaccinia Virion at Increased Resolution

Authors:  Tuan Ngo; Yeva Mirzakhanyan; Nissin Moussatche; Paul David Gershon
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

2.  Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry.

Authors:  Lalita Priyamvada; Wouter W Kallemeijn; Monica Faronato; Kimberly Wilkins; Cynthia S Goldsmith; Catherine A Cotter; Suany Ojeda; Roberto Solari; Bernard Moss; Edward W Tate; Panayampalli Subbian Satheshkumar
Journal:  PLoS Pathog       Date:  2022-10-10       Impact factor: 7.464

Review 3.  Membrane fusion during poxvirus entry.

Authors:  Bernard Moss
Journal:  Semin Cell Dev Biol       Date:  2016-07-14       Impact factor: 7.727

4.  An improved method and cost effective strategy for soluble expression and purification of human N-myristoyltransferase 1 in E. coli.

Authors:  Sujeet Kumar; Rajendra K Sharma
Journal:  Mol Cell Biochem       Date:  2014-03-26       Impact factor: 3.396

Review 5.  Poxvirus cell entry: how many proteins does it take?

Authors:  Bernard Moss
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

6.  The 2.1 Å structure of protein F9 and its comparison to L1, two components of the conserved poxvirus entry-fusion complex.

Authors:  Ulrike S Diesterbeck; Apostolos G Gittis; David N Garboczi; Bernard Moss
Journal:  Sci Rep       Date:  2018-11-14       Impact factor: 4.379

7.  Identification and screening of host proteins interacting with ORFV-ORF047 protein.

Authors:  Guohua Chen; Xiaobing He; Huaijie Jia; Yongxiang Fang; Xiaoxia Wang; Zhongzi Lou; Fan Yang; Weike Li; Zhizhong Jing
Journal:  Virol J       Date:  2021-01-26       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.